Nanobiotix Sa - Adr Share Price (NASDAQ: NBTX)

$8.95

▲

-0.29

(-3.14%)

Last updated on August 30, 2025 at 1:27 am IST

$₹

Check the interactive Nanobiotix Sa - Adr Stock chart to analyse performance

Nanobiotix Sa - Adr Key Stats

Check Nanobiotix Sa - Adr key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$9.24
Open	$8.97
Market Capitalization	$442.8M
Today's Volume	$8.6K
Revenue TTM	$-7.2M
EBITDA	$-67.7M
Earnings Per Share (EPS)	$-1.68
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-198.69%

Stock Returns calculator for Nanobiotix Sa - Adr Stock including INR - Dollar returns

The Nanobiotix Sa - Adr stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Nanobiotix Sa - Adr investment value today

Current value as on today

₹1,75,113

Returns

₹75,113

(+75.11%)

Returns from Nanobiotix Sa - Adr Stock

₹69,829 (+69.83%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Nanobiotix Sa - Adr Stock

-69%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Nanobiotix Sa - Adr Stock from India on INDmoney has decreased by -69% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Nanobiotix Sa - Adr

Name
Holdings %
Name
Holdings %
Johnson & Johnson
11.74%
Jane Street Group LLC
0.02%
Geode Capital Management, LLC
0.02%
Morgan Stanley - Brokerage Accounts
0.01%
UBS Group AG
0.01%

Analyst Recommendation on Nanobiotix Sa - Adr Stock

Rating

Trend

Buy

90%Buy

10%Hold

0%Sell

Based on 10 Wall street analysts offering stock ratings for Nanobiotix Sa - Adr(by analysts ranked 0 to 5 stars)

Nanobiotix Sa - Adr Share Price Target

What analysts predicted

Downside of 15.0%

Target:

$7.61

Current:

$8.95

Nanobiotix Sa - Adr share price target is $7.61, a slight Downside of 15.0% compared to current price of $8.95 as per analysts' prediction.

Nanobiotix Sa - Adr Stock Insights

Price Movement
In the last 7 days, NBTX stock has moved down by -8.5%
Decreasing Revenue
Revenue is down for the last 3 quarters, 32.91M → -20.89M (in $), with an average decrease of 198.4% per quarter
Decreasing Net Profit
Netprofit is down for the last 4 quarters, -5.80M → -46.26M (in $), with an average decrease of 100.0% per quarter
NBTX vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 15.9%
Price to Sales
ForNBTX every $1 of sales, investors are willing to pay $-59.0, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Nanobiotix Sa - Adr Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$75.6K	↓ 41.38%
Net Income	$-56.6M	↑ 70.31%
Net Profit Margin	-74.9K%	↓ 49102.59%

	FY20	Y/Y Change
Revenue	$60.8K	↓ 26.47%
Net Income	$-40.9M	↓ 33.96%
Net Profit Margin	-67.2K%	↑ 7629.0%

	FY21	Y/Y Change
Revenue	$11.3K	↓ 80.0%
Net Income	$-53.1M	↑ 39.8%
Net Profit Margin	-470.0K%	↓ 402794.0%

	FY22	Y/Y Change
Revenue	$5.1M	↑ 47660.0%
Net Income	$-60.4M	↑ 21.36%
Net Profit Margin	-1.2K%	↑ 468845.63%

	FY23	Y/Y Change
Revenue	$39.5M	↑ 658.12%
Net Income	$-43.3M	↓ 30.4%
Net Profit Margin	-109.64%	↑ 1084.73%

	FY24	Y/Y Change
Revenue	$-12.1M	↓ 132.06%
Net Income	$-71.3M	↑ 71.62%
Net Profit Margin	586.89%	↑ 696.53%

Q1 FY23

Q2 FY23

Q3 FY23

Q1 FY24

Q2 FY24

Q1 FY25

	Q1 FY23	Q/Q Change
Revenue	$1.8M	-
Net Income	$-32.8M	-
Net Profit Margin	-1.8K%	-

	Q2 FY23	Q/Q Change
Revenue	$3.6M	↑ 91.06%
Net Income	$-30.5M	↓ 8.42%
Net Profit Margin	-853.29%	↑ 927.04%

	Q3 FY23	Q/Q Change
Revenue	$16.5M	↑ 399.77%
Net Income	$-5.8M	↓ 79.36%
Net Profit Margin	-35.25%	↑ 818.04%

	Q1 FY24	Q/Q Change
Revenue	$32.9M	↑ 100.0%
Net Income	$-11.6M	↑ 100.0%
Net Profit Margin	-35.25%	↑ 0.0%

	Q2 FY24	Q/Q Change
Revenue	$9.3M	↓ 71.78%
Net Income	$-21.9M	↑ 88.54%
Net Profit Margin	-235.46%	↓ 200.21%

	Q1 FY25	Q/Q Change
Revenue	$-20.9M	↓ 324.98%
Net Income	$-46.3M	↑ 111.5%
Net Profit Margin	221.36%	↑ 456.82%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$75.6K	↓ 41.38%

	FY20	Y/Y Change
Profit	$60.8K	↓ 26.47%

	FY21	Y/Y Change
Profit	$11.3K	↓ 80.0%

	FY22	Y/Y Change
Profit	$4.0M	↑ 37810.0%

	FY23	Y/Y Change
Profit	$39.5M	↑ 855.1%

	FY24	Y/Y Change
Profit	$-12.1M	↓ 132.06%

Q1 FY23

Q2 FY23

Q3 FY23

Q1 FY24

Q2 FY24

Q1 FY25

	Q1 FY23	Q/Q Change
Profit	$1.0M	-

	Q2 FY23	Q/Q Change
Profit	$3.6M	↑ 239.66%

	Q3 FY23	Q/Q Change
Profit	$16.5M	↑ 399.77%

	Q1 FY24	Q/Q Change
Profit	$32.9M	↑ 100.0%

	Q2 FY24	Q/Q Change
Profit	$9.3M	↓ 71.78%

	Q1 FY25	Q/Q Change
Profit	$-20.9M	↓ 324.98%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-45.7M	↑ 58.43%
Investing Cash Flow	$-1.6M	↓ 2154.93%
Financing Cash Flow	$46.1M	↑ 179.39%

	FY20	Y/Y Change
Operating Cash Flow	$-33.5M	↓ 33.11%
Investing Cash Flow	$-136.2K	↓ 92.32%
Financing Cash Flow	$135.9M	↑ 169.39%

	FY21	Y/Y Change
Operating Cash Flow	$-33.8M	↑ 8.48%
Investing Cash Flow	$-273.6K	↑ 116.07%
Financing Cash Flow	$-5.9M	↓ 104.63%

	FY22	Y/Y Change
Operating Cash Flow	$-39.3M	↑ 24.21%
Investing Cash Flow	$146.0K	↓ 157.02%
Financing Cash Flow	$-6.0M	↑ 9.09%

	FY23	Y/Y Change
Operating Cash Flow	$-13.6M	↓ 66.38%
Investing Cash Flow	$-380.7K	↓ 352.9%
Financing Cash Flow	$51.0M	↓ 927.66%

	FY24	Y/Y Change
Operating Cash Flow	$-20.5M	↑ 56.71%
Investing Cash Flow	$-999.1K	↑ 173.64%
Financing Cash Flow	$-5.4M	↓ 110.98%

Q1 FY23

Q2 FY23

Q1 FY24

Q2 FY24

Q1 FY25

	Q1 FY23	Q/Q Change
Operating Cash Flow	$-21.6M	↑ 105.68%
Investing Cash Flow	$91.0K	↑ 100.0%
Financing Cash Flow	$-1.7M	↑ 48.16%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-19.1M	↓ 12.74%
Investing Cash Flow	$-354.7K	↓ 484.71%
Financing Cash Flow	$-2.0M	↑ 15.61%

	Q1 FY24	Q/Q Change
Operating Cash Flow	$4.8M	↑ 100.0%
Investing Cash Flow	$-22.0K	-
Financing Cash Flow	$48.9M	↑ 100.0%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-5.8M	↓ 221.61%
Investing Cash Flow	$-500.0K	↑ 2172.73%
Financing Cash Flow	$-2.7M	↓ 105.43%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-13.7M	↑ 135.01%
Investing Cash Flow	$-455.0K	↓ 9.0%
Financing Cash Flow	$-2.5M	↓ 6.59%

Nanobiotix Sa - Adr Technicals Summary

Sell

Neutral

Buy

Nanobiotix Sa - Adr is currently in a neutral trading position according to technical analysis indicators.

Nanobiotix Sa - Adr Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Nanobiotix Sa - Adr	35.88%	160.93%	75.33%	143.8%	-36.19%
Regeneron Pharmaceuticals, Inc.	3.92%	-15.2%	-50.31%	-3.3%	-2.01%
Beone Medicines Ltd	2.49%	24.81%	62.78%	79.11%	29.69%
Vertex Pharmaceuticals Incorporated	-15.42%	-19.13%	-17.84%	34.68%	41.87%
Alnylam Pharmaceuticals, Inc.	11.08%	83.28%	75.87%	111.28%	242.25%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Nanobiotix Sa - Adr	NA	NA	NA	-0.69	-1.99	-0.53	NA	-1.39
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Nanobiotix Sa - Adr	Buy	$442.8M	-36.19%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-2.01%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	29.69%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	41.87%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	242.25%	NA	-12.96%

About Nanobiotix Sa - Adr

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.

Organization	Nanobiotix Sa - Adr
Employees	108
CEO	Mr. Laurent Levy Ph.D.
Industry	Healthcare

Key Management of Nanobiotix Sa - Adr

Name	Title
Mr. Laurent Levy Ph.D.	Co-Founder, President of the Executive Board & CEO
Mr. Bart Van Rhijn	Chief Financial & Business Officer and Member of Executive Board
Ms. Anne-Juliette Hermant M.A.	Chief People Officer & Member of Executive Board
Dr. Louis Kayitalire M.D.	Chief Medical Officer & Member of Executive Board
Mr. Earl J. Bergey Ph.d.	Co-Founder
Mr. Brandon Owens	VP of Strategic Marketing & Corporate Communication
Ms. Margaret Galluzzi	VP & Global Head of Clinical Operations
Dr. Leonard A. Farber M.D.	Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board

Important FAQs about investing in NBTX Stock from India :

What is Nanobiotix Sa - Adr share price today?

Nanobiotix Sa - Adr share price today is $8.95 as on August 30, 2025 at 1:27 am IST at the close of the market. Nanobiotix Sa - Adr share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for Nanobiotix Sa - Adr share?

Nanobiotix Sa - Adr share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. Nanobiotix Sa - Adr stock price today i.e. August 30, 2025 at 1:27 am IST is closed at $8.95, lower by 15.49% versus the 52 week high.

How to invest in Nanobiotix Sa - Adr Stock (NBTX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Nanobiotix Sa - Adr on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Nanobiotix Sa - Adr Shares that will get you 0.1676 shares as per Nanobiotix Sa - Adr share price of $8.95 per share as on August 30, 2025 at 1:27 am IST.

What is the minimum amount required to buy Nanobiotix Sa - Adr Stock (NBTX) from India?

Indian investors can start investing in Nanobiotix Sa - Adr (NBTX) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Nanobiotix Sa - Adr stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Nanobiotix Sa - Adr share’s latest price of $8.95 as on August 30, 2025 at 1:27 am IST, you will get 1.1173 shares of Nanobiotix Sa - Adr. Learn more about fractional shares .

What are the returns that Nanobiotix Sa - Adr has given to Indian investors in the last 5 years?

Nanobiotix Sa - Adr stock has given -36.19% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?